By Cornelius F. Waller (auth.), Uwe M. Martens (eds.)
Extensive examine into the molecular mechanisms of melanoma illness has heralded a brand new age of detailed treatment. In malignant cells, key proteins which are the most important to tumor progress and survival are actually being particular at once with rationally designed inhibitors. except monoclonal antibodies, small molecule therapeutics comparable to oncogenic protein kinase inhibitors are attracting an unlimited quantity of investigational realization. This textbook, written via stated specialists, offers a huge review of the small molecules at the moment used for the remedy of malignant ailments and discusses fascinating novel compounds which are within the means of scientific improvement to wrestle cancer.
Read Online or Download Small Molecules in Oncology PDF
Best oncology books
Contemporary reviews of vascular biology utilizing molecular biology innovations have began to show a formerly unsuspected complexity of the vascular responses to nutrition and actual job, therefore explaining on the molecular point how fit existence have interaction with human genes and the way they have an effect on phenotype expression, even relating to detrimental genes.
Puppy and PET-CT in Oncology describes the rules of positron emission tomography and is an invaluable source for incorporating the process in medical perform. In a transparent and easy model, the ebook bargains instructive info and overviews of the fundamental ideas of puppy and PET-CT in addition to the regimen scientific puppy scanning methods for all vital oncological symptoms.
- Gene Therapy of Cancer: Methods and Protocols
- Radiosensitizers and Radiochemotherapy in the Treatment of Cancer
- The EGF Receptor Family: Biologic Mechanisms and Role in Cancer
- Camptothecins in Cancer Therapy
Extra info for Small Molecules in Oncology
N Engl J Med 353:123–132 Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 20: 2607–2615 31 Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177–193 Thomas MB, Chadha R, Glover K (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059–1067 Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
6 months, respectively. The results are encouraging, but have to be interpreted with caution due to patient selection bias and the small sample size and short follow-up time. Together, sorafenib is the standard of care in patients with advanced HCC as a result of robust data obtained in the setting of phase III investigations both in the West and Asia. The role of erlotinib and erlotinib combinations has to be explored in randomised phase II and III studies. In fact, a phase III study of erlotinib plus bevacizumab against sorafenib is under consideration within the North American GI Steering Committee Hepatobiliary Task Force.
Nature 344:251–253 Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J et al (2008) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111:1039–1043 Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.